HomeProductsBioactive CompoundsCell CycleROCKAfuresertib
Chemical structure of CAS 1047644-62-1

Afuresertib

CAS No.1047644-62-1
MDL No.N/A
MFC18H17Cl2FN4OS
MW427.30
InChI KeyAFJRDFWMXUECEW-LBPRGKRZSA-N

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
- -On RequestOn Request
Custom synthesis and bulk supply options are available upon request.

Product Information

N-[(2S)-1-amino-3-(3-fluorophenyl)propan-2-yl]-5-chloro-4-(4-chloro-2-methyl-3-pyrazolyl)-2-thiophenecarboxamide is an amphetamine.

CAS No.1047644-62-1
Product NameAfuresertib

Biological Targets

AKT2·AKT3·AKT1

Associated Conditions

ovarian cancer·prostate cancer·multiple myeloma·neoplasm·cancer·
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

PI3K/AKT inhibitors aggravate death receptor-mediated hepatocyte apoptosis and liver injury.

Toxicology and applied pharmacology • Vol. 381 • 2019
PMID: 31445927DOI: 10.1016/j.taap.2019.114729

Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research • Vol. 25, Issue 5 • 2019
PMID: 30563934DOI: 10.1158/1078-0432.CCR-18-2277

miRNA‑145 inhibits myocardial infarction‑induced apoptosis through autophagy via Akt3/mTOR signaling pathway in vitro and in vivo.

International journal of molecular medicine • Vol. 42, Issue 3 • 2018
PMID: 29956747PMC: PMC6089768DOI: 10.3892/ijmm.2018.3748

Clinical resistance associated with a novel MAP2K1 mutation in a patient with Langerhans cell histiocytosis.

Pediatric blood & cancer • Vol. 65, Issue 9 • 2018
PMID: 29768711DOI: 10.1002/pbc.27237

Documentation

Similar Products